Cost considerations could factor into the choice of metastatic colorectal cancer (mCRC) treatment. The present real-world observational study of 2352 mCRC patients in the United States found that the per-patient monthly health care costs for first-line (1L) or 1L through second-line therapy were substantially greater for patients treated with 1L cetuximab-containing versus bevacizumab-containing regimens. Such cost implications could be meaningful in real-world clinical practice. Background: The present study examined real-world direct health care costs for metastatic colorectal cancer (mCRC) patients initiating first-line (1L) bevacizumab (BEV)-or cetuximab (CET)-containing regimen in 1L or 1L-throughsecond-line (1L-2L) therapy. Patients and Methods: Using a large US insurance claims database, patients with mCRC initiating 1L BEV-or 1L CET-containing regimen from January 1, 2008 to September 30, 2014 were identified. The per-patient per-month (PPPM) all-cause health care costs (2014 US dollars) were measured during 1L therapy and, for patients continuing to a 2L biologic-containing regimen, 1L-2L therapy. Multivariable regression analyses were used to compare PPPM total health care costs between patients initiating a 1L BEV-versus 1L CET-containing regimen. Results: A total of 6095 patients initiating a 1L BEV-and 453 initiating a 1L CET-containing regimen were evaluated for 1L costs; 2218 patients initiating a 1L BEV-and 134 initiating a 1L CET-containing regimen were evaluated for 1L-2L costs. In 1L therapy, 1L CET had adjusted PPPM costs that were $3135 (95% confidence interval [CI], $1174-$5040; P < .001) greater on average than 1L BEV. In 1L-2L therapy, 1L BEV-2L CET had adjusted PPPM costs that were $1402 (95% CI, $1365-$1442; P ¼ .010) greater than those for 1L BEV-2L BEV, and 1L CET-2L BEV had adjusted PPPM costs that were $4279 (95% CI, $4167-$4400; P ¼ .001) greater on average than those for 1L BEV-2L BEV. The adjusted PPPM cost differences for 1L BEV-2L other biologic or 1L CET-2L other biologic agent were numerically greater but statistically insignificant. Conclusion: PPPM total health care costs for 1L and 2L therapy tended to be greater for patients treated with 1L CET-containing regimens than for 1L BEV-containing regimens. Also, continuing treatment with BEV-containing regimens 1L-2L was less costly than switching between BEV and CET. The cost differences between BEV and CET hold important implications for treatment decisions of mCRC patients in real-world clinical practice.
Introduction
Colorectal cancer (CRC) is the third most commonly diagnosed cancer among men and women in the United States. 1 Approximately 20% of patients have metastatic CRC (mCRC) at diagnosis, with more patients developing progression to mCRC over time. 1 The treatment options for mCRC have been increasing, in part owing to advances in new chemotherapy drugs and expanded indications for biologic agents. In the United States, 5 biologic agents have been approved by the US Food and Drug Administration for first-or later-line treatment of mCRC, including bevacizumab (BEV), cetuximab (CET), panitumumab (PAN), regorafenib (REG), and ziv-aflibercept (ZAF). [2] [3] [4] [5] [6] Of these biologic agents, BEV and CET have been indicated for the treatment of mCRC for the longest duration and are currently the most commonly used agents in the treatment of mCRC. BEV is a vascular endothelial growth factor-specific angiogenesis inhibitor indicated for first-line (1L) and second-line (2L) treatment of mCRC with intravenous 5-fluorouracil (5-FU)ebased chemotherapy and for 2L treatment of patients with progression during 1L BEV-containing regimen. 2 CET is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of RAS wild-type, EGFR-expressing mCRC for 1L treatment with concomitant FOLFIRI (folinic acid, 5-FU, irinotecan) and as single agent or combined with irinotecan in patients with refractory disease. 3 The CALGB (Cancer and Leukemia Group B) 80405 trial, the largest phase III trial designed to compare the overall survival with chemotherapy plus BEV regimens against that of chemotherapy plus CET regimens for 1L treatment of KRAS wild-type mCRC, demonstrated no difference in efficacy between BEV and CET in 1L KRAS wild-type patients. 7 Aside from efficacy, other factors that can influence the choice between BEV and CET for 1L treatment of mCRC include tolerability, right-side versus left-side tumor location, physician and patient preferences, specific treatment goals, and cancer regimen costs. An economic analysis of CALGB 80405 showed that chemotherapy plus BEV regimens cost less and achieved similar survival and quality-adjusted survival as chemotherapy plus CET regimens for 1L treatment of KRAS wild-type mCRC. However, currently, little published information is available regarding the real-world comparative costs of BEV and CET. Two previous observational studies compared the health care costs between mCRC patients initiating 2L BEV-versus CET-containing regimens and reported that patients initiating CET-containing regimens had monthly total health care costs that were > $2000 greater than those receiving BEV-containing regimens. 8, 9 However, no published information has yet compared the real-world health care costs between BEV-versus CET-containing regimens in 1L treatment nor is information available on how the costs compare between these regimens through 2L treatment. Thus, the present study addressed 2 objectives. The first was to compare the health care costs during 1L therapy between mCRC patients treated with a 1L BEV-containing or 1L CET-containing regimen (the 1L comparison) The second was to compare the health care costs during 1L through 2L therapy between mCRC patients treated with a 1L BEV-or 1L CET-containing regimen and continuing to a 2L biologic-containing regimen (BEV, CET, PAN, REG, or ZAF; the treatment sequencing comparison).
Patients and Methods

Data Source
We performed a retrospective, observational cohort study based on US administrative insurance claims data for period spanning July 1, 2007 through September 30, 2014. The data were extracted from the Truven Health MarketScan Commercial and Medicare supplemental databases (Truven Health Analytics Inc, Ann Arbor, MI). These databases include inpatient medical, outpatient medical, and outpatient pharmacy claims data and insurance enrollment and demographic information collected from > 300 large self-insured US employers and more than 25 US health plans.
The commercial database includes information for individuals with employer-sponsored health insurance who were aged < 65 years, including the primary insured and spouses or dependents covered under the primary's insurance plan. The Medicare supplemental database includes information for those who are Medicare-eligible (most of whom were aged ! 65 years) and have both traditional Medicare coverage and a Medicare supplemental insurance plan. The Medicare supplemental database includes both the Medicare-paid and supplemental-paid components of reimbursed insurance claims. During the study period, the databases included insurance claims for > 100 million unique individuals. The study databases satisfy Sections 164.514 (a)-(b)1ii of the Health Insurance Portability and Accountability Act of 1996 privacy rule regarding the determination and documentation of statistically de-identified data. The present study did not involve the collection, use, or transmittal of individually identifiable data; therefore, institutional review board review or approval was not required. Figure 1 depicts key elements of the study design and periods relevant to the process of patient selection. Patients meeting all the following study eligibility criteria were included in the 1L comparison: ! 1 nondiagnostic medical claim (excluding medical claims that could have been associated with a diagnostic workup to rule out a given condition) with an "International Classification of Diseases, Ninth Revision, Clinical Modification" (ICD-9-CM) diagnosis code for colorectal cancer (ICD-9-CM 153.xx, 154.0x, 154.1x, 154.8x) from January 1, 2008 to September 30, 2014; ! 1 nondiagnostic medical claim with an ICD-9-CM code for metastasis 196.8x, .xx) from January 1, 2008 to September 30, 2014 (date of first observed metastasis claim for each patient designated as patient's metastasis date [ Figure 1] ); age ! 18 years on metastasis date; a 1L treatment regimen containing BEV or CET after metastasis date (start of 1L therapy designated as 1L index date [ Figure 1] ); 6 months of continuous enrollment in medical and pharmacy benefits immediately before metastasis date through 1 month after 1L index date; and no evidence of multiple biologic agents included in 1L therapy. Patients were excluded if they had nondiagnostic medical claims with an ICD-9-CM diagnosis code for metastasis in the 6 months immediately before the metastasis date; nondiagnostic medical claims with an ICD-9-CM diagnosis code for non-CRC primary cancer for which BEV, CET, or REG is indicated (ICD-9-CM 140.xx-146.xx, 148.xx-149.xx, 160.xx-161.xx, 162.2x-162.9x, 180.xx, 189.0x, 191.xx) in the 6 months immediately before the metastasis date; and claims for any biologic agents (BEV, CET, PAN, REG, or ZAF) before the metastasis date.
Patient Selection Criteria
Patients meeting the following additional study eligibility criteria were included in the treatment sequencing comparison: 2L treatment regimen containing BEV, CET, PAN, REG, or ZAF (start of 2L therapy designated as 2L index date [ Figure 1] ); continuous enrollment in medical and pharmacy benefits from metastasis date through 1 month after 2L index date; and no evidence of multiple biologic agents in 2L therapy.
Lines of Therapy Construction and Follow-up
The present study's algorithm for construction of the therapy lines was adapted from a validated administrative claims-based algorithm. 8 As shown in Figure 1 , the first claim for a CRC treatment agent occurring after the metastasis date was designated the 1L index date. The CRC treatment regimens included chemotherapy agents (5-FU/capecitabine, oxaliplatin, irinotecan) and biologic agents (BEV, CET, PAN, REG, or ZAF). The 1L therapy regimen included all CRC treatment agents added within 28 days of the 1L index date, with the exception that BEV and ZAF could be added 28 to 120 days after the 1L index date. The addition of BEV and ZAF for 28 to 120 days after the 1L index date was allowed to account for treatment delay or treatment suspension that could have been due to major surgery performed at the discovery of metastasis. The duration of 1L therapy began on the 1L index date and ended at the date of the earliest occurrence of (1) the appearance of a new agent not included in the 1L therapy regimen (including the beginning of 2L therapy); (2) a gap of > 120 days for all agents in the 1L therapy regimen (the end date was the last day with any therapy agent available according to the days supplied for oral agents and recommended treatment intervals for intravenous agents); (3) inpatient death; (4) disenrollment from health insurance; or (5) the end of study period (September 30, 2014).
For patients who initiated 2L therapy, the rules applied for 1L therapy construction and 1L therapy duration were also applied to 2L therapy.
Outcomes and Covariates
All study variables were measured using the insurance enrollment records or inpatient medical, outpatient medical, and outpatient pharmaceutical claims data using ICD-9-CM diagnosis and procedure codes, Current Procedural Terminology codes, Healthcare Common Procedure Coding System codes, and National Drug Codes, as appropriate.
The study outcomes were health care usage and costs, measured during 1L and 2L therapy and expressed in per-patient per-month (PPPM) units to account for the variable length of the therapy lines. Health care usage and costs were categorized as follows: inpatient medical, outpatient medical (subdivided by emergency department, office visits, and other outpatient), outpatient pharmacy, excluding the cancer regimen, and cancer regimen costs (chemotherapy and biologic drug and administration costs). Health care costs were adjusted to 2014 US dollars using the Medical Care component of the Consumer Price Index 10 and were measured using the financial fields in the administrative claims in the MarketScan Databases, including gross covered payments for all health care services or products (ie, the amount eligible for payment after applying pricing guidelines such as fee schedules and discounts but including deductibles, copayments, and coordination of benefits). Costs for services provided under capitated payment arrangements were imputed using a Truven Health Analytics algorithm that computes a payment "proxy" for health care services used, according to the average payments for noncapitated claims at the region, year, and procedure level within the MarketScan databases. This algorithm has been used in the published health economic data for multiple disease areas. 11 Study covariates, including patient demographics and baseline clinical characteristics, were measured to describe the study sample and used for adjustment in the multivariable analyses as described in the subsequent sections. Demographic data were measured as of the index date using enrollment data and included age, sex, US Census Bureau geographic region of residence, health plan type, and year of 1L index date. Unless otherwise noted, the clinical characteristics were measured during the 6-month period immediately before the 1L index date using medical and prescription claims data and included the National Cancer Institute Comorbidity Index, an aggregate measure of comorbidity expressed as a numeric score according the presence of select diagnoses for various conditions, excluding cancer diagnoses, each with specific weights ranging from 1 to 6 points. 12 They also included the number of unique National Drug Codes and the number of unique ICD-9-CM diagnosis codes at the 3-digit level of specificity, both of which have been shown to be predictive of future health care costs, 13 the total health care costs, metastatic site, resection surgery, radiation treatment, and chemotherapy.
Cost of Treating Colorectal Cancer Patients
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Statistical Analysis
Descriptive statistics were used to summarize all study variables. In the 1L comparison, descriptive statistics were stratified by regimen (1L BEV-vs. 1L CET-containing regimens). In the treatment sequencing comparison, descriptive statistics were stratified by the following treatment sequences: 1L BEV-2L BEV, 1L BEV-2L CET, 1L BEV-2L PAN, 1L BEV-2L other biologic agent (ie, REG or ZAF), 1L CET-2L BEV, 1L CET-2L CET, and 1L
Multivariable ordinary least squares regression analysis was used to compare the log-transformed monthly total health care costs across the comparison groups, adjusting for all demographic and baseline clinical characteristics. Because some stratifications in the treatment sequencing comparison had very few patients, 2 versions of the outcome model were fitted. In the first, 1L CET-2L other biologic agent and 1L CET-2L CET were collapsed into a single category and 1L BEV-2L PAN and 1L BEV-2L other biologic agent were collapsed into a single category. In the second, all treatment sequences with 1L CET-containing regimens were collapsed into a single category. Recycled prediction was used to generate adjusted predicted health care cost differences between the comparison groups; 500 bootstrap samples were used to calculate the 95% simultaneous confidence intervals (CIs) around the predicted cost differences. P
.05 was considered the threshold for statistical significance, and statistical significance testing was undertaken only in the context of multivariable analysis.
Results
Patients
After application of the study eligibility criteria, 6095 patients treated with 1L BEV-containing regimens and 453 patients treated with 1L CET-containing regimens were included in the 1L comparison. Of these patients, 2218 treated with 1L BEV-containing regimens and 134 treated with 1L CET-containing regimens were included in the treatment sequencing comparison. The sample attrition associated with the application of each study eligibility criterion and the sample sizes of the individual treatment sequences examined in the treatment sequencing comparison are listed in Supplemental Table 1 (available in the online version).
In the 1L comparison, the 1L BEV-containing regimen group was slightly younger, included a greater proportion of women, and had a mean value of administrative claims-based indexes of comorbidity and health status that were indicative of slightly better health status compared with the 1L CET-containing regimen group (Table 1) . A similar general pattern was observed in the treatment sequencing comparison, although the differences in the indexes of comorbidity and health status were attenuated (Table 1) .
In both comparisons (1L and treatment sequencing), BEVcontaining regimens were more likely to contain oxaliplatin and less likely to contain irinotecan compared with CET-containing regimens (Tables 2 and 3 ). In the treatment sequencing comparison, most (72%) patients with 1L BEV also received BEV in 2L. In the 1L comparison, patients were followed up during 1L therapy for a median of 179 days for 1L BEV and 119 days for 1L CET. In the treatment sequencing comparison, patients were followed up during 1L-2L therapy for a median number of 216 days for 1L CET-2L other biologic agents and 363 days for 1L BEV-2L PAN.
Cancer Regimen Costs
In the 1L comparison, unadjusted PPPM cancer regimen costs were greater for 1L CET-containing regimens than for 1L BEVcontaining regimens (Figure 2 , Left). This pattern was Abbreviations: 1L ¼ first line; BEV ¼ bevacizumab-containing regimen; CET ¼ cetuximabcontaining regimen. a 1L therapy attributes measured during 1L therapy follow-up period (see Figure 1) . b With no observed reinitiation of any agents from 1L therapy.
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Clinical Colorectal Cancer December 2017 -391 maintained in the treatment sequencing comparison, with all 1L CET-containing treatment sequences resulting in greater PPPM cancer regimen costs than 1L BEV-containing treatment sequences (Figure 2 , Right). In both comparisons, the cancer regimen costs were primarily driven by the biologic drug costs, and the greater biologic drug costs for CET compared with BEV was the primary driver of differences across the regimens and sequences.
Total Health Care Costs
Cancer regimen costs accounted for 54% to 66% of total costs across the regimens, the largest single component of total costs, followed by outpatient medical costs (24%-34%), inpatient medical costs (4%-15%), and outpatient pharmacy costs (1%-2%; Table 4 ). In the 1L comparison, unadjusted PPPM total health care costs were greater for 1L CET-containing regimens compared with 1L BEV-containing regimens (Table 4 ). This pattern was maintained in the treatment sequencing comparison, with all 1L CETcontaining treatment sequences having greater PPPM total health care costs than 1L BEV-containing treatment sequences (Table 4) .
In the multivariable analyses of the 1L comparison, the PPPM total health care costs were 15% greater (cost ratio [CR], 1.15; 95% CI, 1.09-1.22; P < .001) in 1L CET-containing regimens compared with 1L BEV-containing regimens. This difference equated to an excess cost of $3135 (95% CI, $1174-$5040) monthly (Figure 3 , Left). On multivariable analyses of the treatment sequencing comparison, in which 1L BEV-1L BEV was treated as the reference category, the PPPM total health care costs were 7% greater (CR, 1.07; 95% CI, 1.02-1.13; P ¼ .010) in 1L BEV-2L CET. This difference equated to an excess cost of $1402 (95% CI, $1365-$1442) monthly. The PPPM total health care costs were 21% greater (CR, 1.21; 95% CI, 1.08-1.37; P ¼ .001) for 1L BEV-2L CET, equating to an excess cost of $4279 (95% CI, $4167-$4400; Figure 3 , Right) monthly. The PPPM total health care costs were greater for 1L BEV-2L other biologic agent and 1L CET-2L other biologic agent compared with 1L BEV-2L BEV. However, the differences were not statistically significant. In a sensitivity analysis of the treatment sequencing comparison in which all 1L CET-containing treatment sequences were compared with all 1L BEV-containing treatment sequences, the PPPM total health care costs were 14% greater (CR, 1.14; 95% CI, 1.05-1.24; P ¼ .002), equating to an excess cost of $2736 (95% CI, $953-$4573; data not shown).
Discussion
To the best of our knowledge, this is the first study to compare real-world health care costs between BEV-and CET-containing regimens in 1L and 1L-2L therapy. Two previous observational studies compared the health care costs between mCRC patients initiating BEV-versus CET-containing regimens in 2L therapy and reported that patients initiating CET-containing regimens had perpatient monthly health care costs that were > $2000 greater. 8, 9 This is generally consistent with the findings from the present study, which found that 1L PPPM total health care costs were $3135 greater for patients initiating 1L CET than to 1L BEV. In both of the previous analyses and in the present analysis, a major driver of the differences in costs was the greater biologic drug costs for the CET groups. Figure 1) . 2 Regorafenib or Ziv-aflibercept. 3 Panitumumab, Regorafenib, or Zivaflibercept Abbreviations: BEV ¼ bevacizumab-containing regimen; CET ¼ cetuximab-containing regimen; ED ¼ emergency department.
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14 Thus, the real-world evidence provided by the present study corroborates the collective findings generated from that clinical trial-based economic modeling study. Similar to other real-world observational studies evaluating the sequence of 1L-2L treatments for mCRC, the present study found that most patients initiating 1L BEV continued to a 2L BEVcontaining regimen, with fewer patients switching to a 2L CETcontaining regimen or other targeted therapy. 15, 16 Fewer patients initiated 1L CET, which previous studies have suggested might be due, in part, to later approval and slower uptake of CET as 1L therapy. 15, 16 The present study found that 1L CET patients were equally as likely to continue to a 2L CET-containing regimen as to switch to a 2L BEV-containing regimen.
As the patients progressed from 1L through 2L treatment sequences, the differences in costs observed between 1L CETcontaining regimens and 1L BEV-containing containing regimens persisted through 2L therapy. The adjusted PPPM total health care costs through 1L and 2L were $3135 greater for patients initiating 1L CET-containing regimens than for 1L BEV-2L BEV regimens. Switching treatment regimens to a different 2L therapy corresponded to greater PPPM total health care costs for 1L-2L. Patients initiating 1L BEV-containing regimens and proceeding to a 2L CET-containing regimens had $1402 greater PPPM health care costs compared with the costs of 1L BEV-2L BEV. Patients initiating 1L CET-containing regimens and proceeding to 2L BEVcontaining regimens had $4279 greater PPPM health care costs compared with the costs of 1L BEV-2L BEV. The differences in costs were smaller for patients switching to newer 2L treatments such as other EGFR antagonists or other targeted therapies. However, these sample sizes were limited by the later approval for these treatments for mCRC. Future research should investigate the longterm effects of newer treatments on differences in health care costs for patients with mCRC.
The present study had limitations. First, because RAS testing results were not available for our data set, the study population could not be restricted to RAS wild-type patients. Also, because of the label restriction of CET to KRAS wild-type patients, it can be assumed that patients initiating 1L CET would have predominantly had KRAS wildtype disease, and the disease of patients initiating 1L BEV would have been a mixture of KRAS genotypes. Because patients with KRAS wildtype mCRC have a better prognosis and more treatment options, the results could have been biased by the overrepresentation of KRAS wildtype in the CET therapy lines. Second, our study period extended back to a time before CET was approved for 1L treatment of mCRC. We decided to maximize the sample size because of the knowledge that in real-world populations, treatment patterns might not always follow labeled instructions. In a post hoc sensitivity analysis, we analyzed the 1L comparison results when restricting the study population to Figure 3 Multivariable-adjusted Per-patient Per-month (PPPM) Excess Total Health Care Costs, 2014 US Dollars 1 . 1 Costs Measured During First-line (1L) and Second-line (2L) Therapy Follow-up Periods, Excluding Interval Between Therapy Lines (see Figure 1) ; "Other" in 1L BEV-2L Other and 1L CET-2L Other Corresponds to Panitumumab, Regorafenib, or Ziv-aflibercept. 2 Abbreviations: BEV ¼ bevacizumab-containing regimen; CET ¼ cetuximab-containing regimen.
Clinical Colorectal Cancer December 2017 -395 individuals initiating 1L therapy after the approval of CET for 1L treatment of mCRC. We found the results were consistent with the primary analysis findings (data not shown). Third, earlier approval of BEV for 1L treatment of mCRC, KRAS genotype, and other factors, such as physician prescribing preferences and biologic drug costs, might have contributed to differences in the number of patients initiating 1L BEV-versus CET-containing regimens. Despite the differences in sample size, the demographic and baseline clinical characteristics were similar for both groups, suggesting these groups are largely representative of the general population of patients with mCRC initiating 1L therapy. Fourth, administrative claims data are not collected for research purposes and are subject to coding inaccuracies that could have introduced measurement error into the variables. Fifth, potential existed for residual confounding even after multivariable adjustment, because clinical information on performance status and stage were not available in this data set. Finally, the present study results were derived from patients with commercial or Medicare plus supplemental health insurance and might not be generalizable to the entire US population, including those with only traditional Medicare coverage, Medicaid coverage, or no insurance.
Conclusion
The present study found that mCRC cancer regimens that contained BEV in 1L therapy were associated with lower cancer regimen and total health care costs than those that contained CET. These cost differences persisted with 2L therapy. The cost differences between BEV and CET hold important implications for the treatment decisions of mCRC patients in real-world clinical practice.
Clinical Practice Points
Two previous observational studies compared health care costs between mCRC patients initiating BEV-versus CET-containing regimens in 2L therapy and reported that patients initiating CET-containing regimens had health care costs that were > $2000 greater. The present study compared real-world health care PPPM costs between BEV-and CET-containing regimens in 1L and 1L-2L therapy. The 1L mCRC cancer regimens containing BEV were associated with lower cancer regimen and total health care costs than those containing CET. The PPPM costs for 1L-2L were greater for 1L CET-versus 1L BEV-containing regimens. Continuing treatment with BEV-containing regimens through 2L therapy was less costly than switching between BEV and CET. The cost differences between BEV and CET hold important implications for the treatment decisions of mCRC patients in real-world clinical practice.
